Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

Stuart Dowall*, V. A. Graham, K. Corbin-Lickfett, C. Empig, K. Schlunegger, C. B. Bruce, L. Easterbrook, R. Hewson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

Original languageEnglish
Article number347903
JournalJournal of Immunology Research
Volume2015
DOIs
Publication statusPublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 S. D. Dowall et al.

Fingerprint

Dive into the research topics of 'Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions'. Together they form a unique fingerprint.

Cite this